文献速递自身炎症与 IgG4 相关病

稳定期IgG4相关性疾病患者撤除免疫抑制剂和小剂量激素(WInS IgG4-RD):一项研究者发起的多中心开放标签随机对照试验

Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
PubMed 文献 · Ann Rheum Dis · 2024-04-11

WInS IgG4-RD试验为多中心开放标签随机对照试验,将146例临床静止至少12个月的IgG4-RD患者按1:1:1随机分为撤除糖皮质激素+免疫抑制剂组、撤激素保留免疫抑制剂组、维持激素+免疫抑制剂组。18个月内疾病复发率三组分别为52.1%、14.2%、12.2%(p<0.001),保留免疫抑制剂(联合或不联合小剂量激素)优于撤除激素+免疫抑制剂。

要点

  • 稳定期IgG4-RD撤除激素+免疫抑制剂组18个月复发率为52.1%。
  • 保留免疫抑制剂组复发率14.2%,维持激素+免疫抑制剂组12.2%(p<0.001)。
  • 保留免疫抑制剂(联合或不联合小剂量激素)在预防复发方面优于撤除激素+免疫抑制剂。

核心结论

  • 对于长期稳定的IgG4-RD患者,保留免疫抑制剂(联合或不联合小剂量激素)在预防复发方面优于撤除激素+免疫抑制剂。

研究设计与样本

  • WInS IgG4-RD试验为研究者发起的多中心开放标签随机对照试验,将146例接受激素+免疫抑制剂维持治疗且临床静止至少12个月的IgG4-RD患者按1:1:1随机分组。

主要发现

  • 18个月随访期内,第1组(撤除激素+免疫抑制剂)48例中25例(52.1%)复发,第2组(撤激素保留免疫抑制剂)49例中7例(14.2%)复发,第3组(维持激素+免疫抑制剂)49例中6例(12.2%)复发(p<0.001)。
  • 第1组RI和PGA的变化显著高于第2组(p<0.001)和第3组(p<0.001)。

关键数值与推荐

  • 主要结局为18个月内疾病复发率:第1组52.1%(25/48)vs 第2组14.2%(7/49)vs 第3组12.2%(6/49)(p<0.001)。
  • 次要结局包括IgG4-RD Responder Index(RI)、Physician's Global Assessment(PGA)、血清IgG4和IgG的变化及不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: IgG4-related disease (IgG4-RD) is an immune-mediated, fibroinflammatory disease. Induction treatment with glucocorticoid (GC) is usually effective, but its tendency of relapse makes the strategy for maintenance treatment a challenge. The WInS IgG4-RD (withdraw immunosuppressants (IMs) and steroid in stable IgG4-RD) trial tested whether discontinuation of GC and IM was feasible in stable IgG4-RD. METHODS: The WInS IgG4-RD trial was a multicentre, open-label, randomised controlled trial. Patients with IgG4-RD receiving GC+IM as maintenance treatment with clinically quiescent disease for at least 12 months were randomised (1:1:1) into three groups: group 1: withdraw GC+IM; group 2: withdraw GC but maintain IM; group 3: maintain GC+IM. The primary outcome was the relapse rate of disease within 18 months. The secondary outcomes included the changes of IgG4-RD Responder Index (RI), Physician's Global Assessment (PGA), serum IgG4 and IgG, as well as adverse events. RESULTS: One hundred and forty-six patients were randomised, with 48 patients in group 1, 49 patients in group 2 and group 3, respectively. Within the 18-month follow-up period, disease relapse occurred in 25 out of 48 (52.1%) patients in group 1 vs 7 out of 49 (14.2%) in group 2 and 6 out of 49 (12.2%) in group 3 (p<0.001). The changes in RI and PGA were significantly higher in group 1 than in group 2 (p<0.001) or group 3 (p<0.001). CONCLUSIONS: The maintenance of IMs, with or without low-dose GC, was found to be superior to withdraw GC+IM in preventing relapse for long-time stable IgG4-RD. TRIAL REGISTRATION NUMBER: NCT04124861.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Peng L, Nie Y, Zhou J, et al. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial. Ann Rheum Dis. 2024. PMID: 38216319. doi:10.1136/ard-2023-224487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。